Kevin Tang was named Chief Executive Officer of Aurinia Pharmaceuticals Inc., effective March 23, 2026. As of November 14, 2026, Aurinia Pharmaceuticals Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 23, 2026, naming 3 appointments (Form 8-K, March 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Aurinia Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Kevin Tang · Role: Chief Executive Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
- · In / out: In · Person: Ryan Cole · Role: Chief Operating Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
- · In / out: In · Person: Michael Hearne · Role: Chief Financial Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
Aurinia Pharmaceuticals Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-23. It names 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Aurinia Pharmaceuticals Inc. files it.
Layoffs on record: 2 filings or notices, latest 2024-11-07 (layoff filings and notices).
Also on the record for Aurinia Pharmaceuticals Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 26, 2026 | Stake report, Schedule 13D/A, by ILJIN SNT Co., Ltd. | 4.4% of the class | 5%+ stakes | Source |
| June 4, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | 10% of the class | 5%+ stakes | Source |
| March 25, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | 9.2% of the class | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC | 9.2% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13D/A, by ILJIN SNT Co., Ltd. | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aurinia Pharmaceuticals Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aurinia Pharmaceuticals Inc. and the records around it.
Aurinia Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Aurinia Pharmaceuticals Inc.
Get an email when Aurinia Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aurinia Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aurinia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aurinia Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-23 | In | Chief Executive Officer | 2026-03-23 | 8-K, 2026-03-23 | |
| 2026-03-23 | In | Chief Operating Officer | 2026-03-23 | 8-K, 2026-03-23 | |
| 2026-03-23 | In | Chief Financial Officer | 2026-03-23 | 8-K, 2026-03-23 |
Who leads Aurinia Pharmaceuticals Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Michael Hearne, appointed, effective 2026-03-23 (filed 2026-03-23).
- Chief Operating Officer: Ryan Cole, appointed, effective 2026-03-23 (filed 2026-03-23).
- Chief Executive Officer: Kevin Tang, appointed, effective 2026-03-23 (filed 2026-03-23).
New leaders reset buying decisions — get the Full Report on Aurinia Pharmaceuticals Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Aurinia Pharmaceuticals Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Aurinia Pharmaceuticals Inc.Every change, in the filing's words
Appointed: Kevin Tang, Chief Executive Officer, effective 2026-03-23
Effective March 23, 2026, the Board of Directors of Aurinia Pharmaceuticals Inc. ("Aurinia") appointed Kevin Tang as Aurinia's Chief Executive Officer and as Aurinia's principal executive officer.
Appointed: Ryan Cole, Chief Operating Officer, effective 2026-03-23
Effective March 23, 2026, Aurinia's Board of Directors appointed Ryan Cole as Aurinia's Chief Operating Officer.
Appointed: Michael Hearne, Chief Financial Officer, effective 2026-03-23
Effective March 23, 2026, Aurinia's Board of Directors appointed Michael Hearne as Aurinia's Chief Financial Officer and as Aurinia's principal financial officer and principal accounting officer.
- Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Mr. Tang, age 59, has served as Chair of Aurinia's Board of Directors since 2024.
- He is President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002.
- From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company.
- In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022.
- Mr. Tang co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020.
- From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012.
- From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group.
- Mr. Tang received a B.S. degree from Duke University.
Tools for this story
Each opens in a new tab, filled in for Aurinia Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
